Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on February 2, 2012. The report announces the issuance of a press release detailing financial results for the fiscal quarter ended December 31, 2011.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the Q4 2011 results have been released.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding commercial and technology progress. Management highlights significant risks that could cause actual results to vary, including:
- Changes in regulatory clinical and guideline developments.
- Insufficient scientific data to meet regulatory standards or failure to receive required approvals.
- Inability to replicate clinical results in actual patient settings.
- Challenges to patent protection by competitors.
- Market size and penetration risks.
- Insufficient revenues to fund further development or meet future capital needs.
- Uncertainties regarding diverse regulatory and marketing requirements globally.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the full text of the press release (Exhibit 99.1).
- Confirm the company's current cash position and runway for future operations.
- Review the status of key regulatory approvals mentioned in the risks section.
- Check for any updates on patent challenges or litigation.